Antihypertensive drugs

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including MSDS and any product information leaflets have been developed and issued under the Authority of the

A prodrug of the potent, long-acting, and selective AT1 receptor antagonist, candesartan 4-16 mg/day effectively reduces diastolic blood pressure and has proved useful in the treatment of hypertension and diabetes.

A prodrug of the potent, long-acting, and selective AT1 receptor antagonist, candesartan 4-16 mg/day effectively reduces diastolic blood pressure and has proved useful in the treatment of hypertension and diabetes.

A prodrug of the potent, long-acting, and selective AT1 receptor antagonist, candesartan 4-16 mg/day effectively reduces diastolic blood pressure and has proved useful in the treatment of hypertension and diabetes.

A prodrug of the potent, long-acting, and selective AT1 receptor antagonist, candesartan 4-16 mg/day effectively reduces diastolic blood pressure and has proved useful in the treatment of hypertension and diabetes.

CI-1033 is a potent, irreversible ATP binding site–directed pan-ErbB tyrosine kinase inhibitor with IC50 in the low nanomolar range for EGFR, HER2, and ErbB-4.

CI-1033 is a potent, irreversible ATP binding site–directed pan-ErbB tyrosine kinase inhibitor with IC50 in the low nanomolar range for EGFR, HER2, and ErbB-4.

CI-1033 is a potent, irreversible ATP binding site–directed pan-ErbB tyrosine kinase inhibitor with IC50 in the low nanomolar range for EGFR, HER2, and ErbB-4.

CI-1033 is a potent, irreversible ATP binding site–directed pan-ErbB tyrosine kinase inhibitor with IC50 in the low nanomolar range for EGFR, HER2, and ErbB-4.

Legal Information Eppendorf is a registered trademark of Eppendorf AG Innova is a registered trademark of Eppendorf, Inc. 

CAPINSERT FOR CRYOVIAL TAN

M38e RX Module, Non-Lock, FactInst (DROP SHIP ONLY)